Suppr超能文献

《中国老年肺炎诊断与治疗专家共识(2024年版)》

[Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition)].

出版信息

Zhonghua Jie He He Hu Xi Za Zhi. 2025 Jan 12;48(1):18-34. doi: 10.3760/cma.j.cn112147-20240611-00328.

Abstract

China is experiencing a demographic shift as its population ages. The elderly population becomes increasingly susceptible to pneumonia. Pneumonia in the elderly is characterized by its insidious onset, rapid progression, multiple comorbidities, poor prognosis, and high morbidity and mortality. Physicians need to pay attention to developing more comprehensive diagnostic evaluations and treatment strategies, and ensuring personalized care to the greatest extent. In order to improve the prevention and management of pneumonia in elderly, this consensus incorporates the latest guidelines and consensus from both domestic and international sources. The latest progress in this research field is also included. The document addresses 17 clinical issues in a question-and-answer format and provides 13 recommendations on the etiology, pathogenesis, clinical diagnosis, treatment, and prevention of pneumonia in older adults. It provides reference for the prevention and treatment of pneumonia in elderly, improving their quality of life, reducing hospitalization and mortality, and promoting healthy aging. The specific recommendations are as follows.The main risk factors for pneumonia in the elderly include age (Recommended Level ⅠA), age-related systemic factors (such as poor physical condition, underlying diseases, and concomitant medications), and specific factors (specifically dysphagia and aspiration). The risk increases progressively with age (Recommended Level Ⅱ-1A).Pneumonia in elderly individuals often presents with an insidious onset and atypical respiratory symptoms, especially in super-elderly patients. Initially, symptoms may include fatigue, loss of appetite, and disturbance of consciousness. Moreover, elderly patients often have underlying conditions such as pulmonary, cardiovascular, and neurological disorders, which can lead to rapid deterioration, multiple complications and sequelae. Pneumonia-related laboratory parameters in the elderly lack typical characteristic changes (Recommended Level ⅢA). The high proportion of comorbidities significantly increases the risk of pneumonia, especially pneumonia caused by drug-resistant bacteria, and the likelihood of a worse prognosis in elderly patients (Recommended Level Ⅱ-2A). Neurological or psychiatric disorders and therapeutic drugs such as antipsychotic drugs increase the risk of pneumonia including aspiration pneumonia, necrotizing pneumonia, lung abscess, hypostatic pneumonia and atelectasis in elderly patients (Recommended Level Ⅱ-2B).For elderly patients with suspected pneumonia, chest CT should be performed as early as possible in cases of long-term bed-ridden patients, aspiration pneumonia, or viral pneumonia (Recommended Level ⅢA). If conventional tests fails to identify the pathogen and empirical treatment proves to be ineffective, or if special pathogen infection such as viruses, severe or complex infection, or immunosuppression is suspected, it is advised to use invasive procedures to obtain bronchoalveolar lavage fluid (BALF), pleural effusion, or lung biopsy, and to conduct molecular biology testing (PCR, mNGS, tNGS, etc.) concurrently with conventional pathogen tests (Recommended Level ⅢA).The pharmacokinetics (PK) changes of antimicrobial drugs in elderly patients and necessity of dosage reduction should be evaluated according to the unique physiological characteristics of the elderly, such as declining body function, the presence of multiple diseases, and potential medication interactions. It is recommended to combine the PK/PD characteristics of antimicrobial drugs and therapeutic drug monitoring (TDM) methods to guide the individualized and precise prescription for elderly patients with pneumonia. This approach aims to ensure efficacy, minimizing the risk of bacterial resistance, and reduce the incidence of adverse reactions (Recommended Level Ⅱ-2B).Timing of treatment: Empiric antimicrobial therapy should be initiated as soon as the diagnosis is made. Except for outpatient clinic visitors with mild symptoms, properly collected respiratory secretions and blood samples should be sent without delay for pathogenic microorganisms testing. During the influenza season, timely empiric antiviral therapy should be initiated without positive result (Recommended Level Ⅱ-1A).Coverage of possible pathogens: Due to the increased detection rate of various pathogens such as gram-negative bacteria, anaerobic bacteria, fungi, etc., the initial treatment should cover the possible pathogens. Individualized treatment should be started according to the estimation of drug resistance risk, the of PK/PD principle, and potential drug side effects (Recommended Level Ⅱ-1A).Appropriate treatments for promoting sputum drainage and airway clearance in elderly pneumonia patients should be chosen after a comprehensive evaluation of the patient's condition. It is crucial to assess the patient's coughing efficacy to avoid asphyxia (Recommended Level ⅢA).We recommend cautious use of glucocorticoids in elderly pneumonia patients. When it is indeed necessary to use glucocorticoids in severe pneumonia cases accompanied by septic shock and hemodynamic instability, it's crucial to tailor drug regimens carefully, monitor closely for adverse reactions, and avoid excessive or prolonged glucocorticoid use (Recommended Level ⅢB).Assessing the swallowing abilities of elderly patients is important, and individuals with dysphagia should undergo swallowing rehabilitation. These measures can help reduce the risk of aspiration pneumonia, such as adopting a semi-recumbent posture, thickened fluids and soft foods, proper dental care, tube feeding, and discontinuing medications that increase the risk of aspiration pneumonia in older patients (Recommended Level ⅡA).We recommend that elderly individuals get an annual influenza virus vaccine (Recommended Level ⅠA), 23-valent pneumococcal polysaccharide vaccine (PPV 23) or the 13-valent pneumococcal conjugate vaccine (PCV 13) to prevent CAP (Recommended Level ⅠB), and COVID-19 vaccine should also be recommended in accordance with national guidelines (Recommended Level ⅠA).Older individuals should quit smoking, limit alcohol intake, participate in moderate-intensity physical activity (Recommended Level Ⅱ-1A), have regular dental examinations, maintain good nutritional status and personal hygiene, and avoid close contact with children with acute viral respiratory infections (Recommended Level Ⅱ-2A).The super-elderly are more likely to experience geriatric syndromes, particularly sarcopenia and frailty, which are closely associated with the occurrence of aspiration pneumonia. Preventing and improving sarcopenia and weakness through nutrition supplement, exercise, cognitive training, etc., can effectively reduce the incidence of pneumonia (Recommended Level ⅢA).We recommend that older adults with chronic underlying medical conditions, who are at increased risk of developing pneumonia, should receive personalized management and comprehensive preventive measures to strengthen the management of underlying diseases. Perioperative care for older patients should be optimized to reduce the risk of postoperative pneumonia (Recommended Level ⅢA).

摘要

随着人口老龄化,中国正经历人口结构转变。老年人群越来越易患肺炎。老年人肺炎具有起病隐匿、进展迅速、合并多种疾病、预后差以及发病率和死亡率高等特点。医生需要重视制定更全面的诊断评估和治疗策略,并最大程度确保个性化护理。为提高老年人肺炎的预防和管理水平,本共识纳入了国内外最新指南和共识,还包括该研究领域的最新进展。该文件以问答形式阐述了17个临床问题,并就老年人肺炎的病因、发病机制、临床诊断、治疗及预防提出了13条建议。它为老年人肺炎的防治、提高其生活质量、降低住院率和死亡率以及促进健康老龄化提供了参考。具体建议如下:

老年人肺炎的主要危险因素包括年龄(推荐等级ⅠA)、与年龄相关的全身因素(如身体状况差、基础疾病和伴随用药)以及特定因素(特别是吞咽困难和误吸)。风险随年龄增长而逐渐增加(推荐等级Ⅱ-1A)。

老年个体肺炎常起病隐匿,有非典型呼吸道症状,尤其是超高龄患者。最初症状可能包括疲劳、食欲不振和意识障碍。此外,老年患者常伴有肺部、心血管和神经系统等基础疾病,可导致病情迅速恶化、出现多种并发症及后遗症。老年人肺炎相关实验室指标缺乏典型特征性变化(推荐等级ⅢA)。合并症比例高显著增加肺炎风险,尤其是耐药菌引起的肺炎,以及老年患者预后较差的可能性(推荐等级Ⅱ-2A)。神经或精神疾病以及抗精神病药物等治疗药物会增加老年患者肺炎风险,包括误吸性肺炎、坏死性肺炎、肺脓肿、坠积性肺炎和肺不张(推荐等级Ⅱ-2B)。

对于疑似肺炎的老年患者,长期卧床患者、误吸性肺炎或病毒性肺炎患者应尽早进行胸部CT检查(推荐等级ⅢA)。如果常规检查未能识别病原体且经验性治疗无效,或怀疑有病毒等特殊病原体感染、严重或复杂感染或免疫抑制,建议采用侵入性操作获取支气管肺泡灌洗液(BALF)、胸腔积液或肺活检,并与常规病原体检测同时进行分子生物学检测(PCR、mNGS、tNGS等)(推荐等级ⅢA)。

应根据老年人独特的生理特征,如身体功能下降、多种疾病并存以及潜在药物相互作用等,评估抗菌药物在老年患者体内的药代动力学(PK)变化及减量必要性。建议结合抗菌药物的PK/PD特性和治疗药物监测(TDM)方法,指导老年肺炎患者的个体化精准用药。该方法旨在确保疗效,最小化细菌耐药风险,并降低不良反应发生率(推荐等级Ⅱ-2B)。

治疗时机

一旦确诊应尽早开始经验性抗菌治疗。除症状轻微的门诊患者外,应及时采集并送检合格的呼吸道分泌物和血样进行病原微生物检测。在流感季节,若未得到阳性结果应及时开始经验性抗病毒治疗(推荐等级Ⅱ-1A)。

可能病原体的覆盖范围

由于革兰阴性菌、厌氧菌、真菌等各种病原体的检出率增加,初始治疗应覆盖可能的病原体。应根据耐药风险评估、PK/PD原则及潜在药物副作用等开始个体化治疗(推荐等级Ⅱ-1A)。

老年肺炎患者应在全面评估病情后选择合适的促进痰液引流和气道清理的治疗方法。评估患者咳嗽效果以避免窒息至关重要(推荐等级ⅢA)。

我们建议老年肺炎患者谨慎使用糖皮质激素。对于伴有感染性休克和血流动力学不稳定的重症肺炎患者,确实需要使用糖皮质激素时,必须仔细调整用药方案,密切监测不良反应,避免糖皮质激素过量或长期使用(推荐等级ⅢB)。

评估老年患者的吞咽能力很重要,吞咽困难者应进行吞咽康复训练。这些措施有助于降低误吸性肺炎风险,如采取半卧位、食用增稠液体和软食、适当的口腔护理、管饲喂养以及停用增加老年患者误吸性肺炎风险的药物(推荐等级ⅡA)。

我们建议老年人每年接种流感病毒疫苗(推荐等级ⅠA)、23价肺炎球菌多糖疫苗(PPV 23)或13价肺炎球菌结合疫苗(PCV 13)以预防社区获得性肺炎(CAP)(推荐等级ⅠB),并且还应根据国家指南推荐接种新冠疫苗(推荐等级ⅠA)。

老年人应戒烟、限制饮酒、参加中等强度体育活动(推荐等级Ⅱ-1A),定期进行口腔检查,保持良好的营养状况和个人卫生,避免与患有急性病毒性呼吸道感染儿童密切接触(推荐等级Ⅱ-2A)。

超高龄者更易出现老年综合征,尤其是肌肉减少症和衰弱,这与误吸性肺炎的发生密切相关。通过营养补充、运动、认知训练等预防和改善肌肉减少症和衰弱,可有效降低肺炎发病率(推荐等级ⅢA)。

我们建议患有慢性基础疾病、肺炎发生风险增加的老年人应接受个性化管理和全面预防措施,加强基础疾病管理。应优化老年患者的围手术期护理以降低术后肺炎风险(推荐等级ⅢA)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验